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The results obtained by liver transplantation (TX) (n = 105) for 
hepatocellular carcinoma (HeC) were compared with those achieved 
by hepatic resection (HX) (n = 76). Overall 1- to 5-year survival rates 
after TX were 66%, 49%, 39%, 36%, and 36%, and those after HX were 
71%, 55%, 47%, 37%, and 33%, respectively. The survival rates after 
TX and HX correlated well with pTNM stages, and the overall sur-
vival rates were similar in each stage between the TX and the HX 
group. However, when HCC was associated with cirrhosis of the liver, 
the survival rates after TX were significantly higher than those after 
HX at each stage of pTNM classification. Tumor recurrence rate was 
high both after TX (43%) and HX (50%), particularly in stage IV-A. 
Tumor recurrence rate was significantly lower after TX than after HX 
in HCCs of stages II and III. Liver TX has established its definite role 
in the treatment of HCC, particularly in the presence of hepatic im-
pairment or cirrhosis of the liver. c 1993 Wiley-Liss. Inc. 
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INTRODUCfION 
In the early trials ofliver transplantation (TX), total 
hepatectomy and liver replacement (orthotopic liver 
TX) were thought to be an ideal therapy for primary 
hepatic malignancy that could not be removed by con-
ventional techniques of subtotal hepatic resection 
(HX). The enthusiasm for this approach was soon 
dampened by the high recurrence rate of original 
malignancies after successful transplantation [1-4], 
and the role of liver TX in cancer therapy has been 
seriously questioned. Nevertheless, the efforts to treat 
malignant tumors by liver TX have been continued 
because of: I) the lack of other effective therapy; 2) 
occasional long-term survival and excellent palliation; 
and 3) the much improved overall survival after liver 
TX with cyclosporine-steroid therapy during the last 
decade. 
Recently we have reviewed our experiences in the 
treatment of hepatocellular ca.rcinoma (HCC) either 
by orthotopic liver TX or by conventional subtotal 
hepatectomy during the era of cyclosporine (1980-
1989) [5]. The comparisons between the results ob-
tained by liver TX and those by HX led us to under-
© 1993 WiJey-Liss, Inc. 
stand the pros and the cons of either therapy in the 
various stages of HCC. 
PATIENTS AND METHODS 
During the to-year period between 1980 and 1989, 
105 patients with HCe were treated by orthotopic 
liver TX under cyclosporine-steroid immunosuppres-
sive therapy and an additional 76 patients by subtotal 
HX at the University of Colorado Health Sciences 
Center (1980) and the University Health Center of 
Pittsburgh (1981-1989). 
Subtotal HX was considered as the first treatment 
of choice for Hee when it was anatomically and 
functionally feasible. Liver TX was used if HX was 
not feasible due to extensive hepatic involvement of 
malignancy or if the underlying liver disease and/or 
hepatic failure precluded this possibility. One third of 
the patients in the transplant group had extensive 
Hee in the normal liver which could only be 
removed by total hepatectomy, one third had Hee 
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TABLE I. pTNM Pathologic Classification of HCe· 
Stage I TI NO MO 
Stage II n NO MO 
Stage III TI NI MO 
T2 NI MO 
T3 NO.NI MO 
Stage IVA T4 AnyN MO 
Stage (VB AnyT AnyN MI 
*T\. Solitary. :S 2 cm. without vascular invasion; n, solitary, :S 2 
em, with vascular invasion. Multiple, one lobe, :S 2 em, without 
vascular invasion; T3. solitary, > 2 em, with vascular invasion. 
Multiple. one lobe, > 2 em, with or without vascular invasion; T4. 
multiple. more than one lobe. Invasion of major branch of portal 
or hepatic veins; N I. regional lymph node; M I. distant metastasis. 
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TABLE II. pTNM Stages of lOS Patient! in TX Group and 
5 Those of 76 Patient! in HX Group 
Years After Operation 
Fig. I. Overall survival rates after liver TX and HX for HCC. 
in advanced cirrhosis of the liver, and one third had 
misdiagnosed HCC in the failing liver for which liver 
TX was performed. 
RFSUL TS AND DISCUSSION 
Overall survivals of the 105 patients who received 
liver TX in the presence of HCC and those of the 76 
patients who underwent HX for HCC were similar as 
shown in Figure 1. As the indication for TX differs 
from that of HX, the comparison between these two 
therapeutic modalities in overall survival rates has lit-
tle value. Therefore. the stages of HCC in the TX 
pTNM stage TX group HX group 
I 4 0 
II 19 19 
III 23 25 
IV-A 59 32 
TOlal 105 76 
group and the HX group were stratified according to 
the pTNM classification (Table I) [6.7] and are shown 
in Table II. 
There were only four patients with stage I HCC. all 
of whom received liver TX. One of the four patients 
died of transplant-related complications. but the other 
three patients were alive. free of tumor 2-5 years after 
TX (l-5-year survival rates of 75%). 
The survival rates after TX and after HX were com-
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Fig. 2. Survival rates after liver TX and after HX for stages II to IV-A HCC. 
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Fig. 3. Survival rates after liver TX and after HX for HCC in 
cirrhosis of the liver. 
pared in pTNM stages II through IV-A, and shown in 
Figure 2. The pTNM stage correlated well with the 
survival rates both in the TX and the HX groups. In 
both groups the survival rates of stage IV-A patients 
were significantly (P < 0.05) lower than those of other 
stages. There was no statistically significant difference 
in the survival rates when they were compared in the 
same pTNM stages between the TX group and the HX 
group (Fig. 2). 
Because the presence of associated cirrhosis of the 
liver with HCC or hepatic dysfunction was a major 
factor in choosing either TX or HX therapy, the sur-
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vival rates were compared between the patients with 
associated cirrhosis and those without it both in the 
TX group and the HX group (Fig. 3). When HCC was 
associated with cirrhosis of the liver, the survival rates 
were significantly (P = 0.001) lower than those with-
out cirrhosis in the HX group, but the survival rates 
were similar in the TX group. The survival rates of the 
TX group were significantly (P = 0.002) higher than 
those of the HX group when HCC was associated with 
cirrhosis of the liver, but they were similar when HCC 
was not associated with cirrhosis. There were no 
4-year survivors after HX among the patients with 
HCC in the cirrhotic liver, but the 5-year survival rate 
after TX was 41 %. 
The survival rates of patients with HCC in the cir-
rhotic liver were compared between the TX group and 
the HX group in the same pTNM stages and are 
shown in Figure 4. The survival rates of the TX group 
were higher than those of the HX group in stages II 
through IV -A, and the difference was most striking in 
stage III. 
The recurrence of HCC was confirmed in 45 
(43%) of the 105 patients in the TX group and in 38 
(50%) of the 76 patients in the HX group during the 
following period (18-132 months). Although overall 
incidence of tumor recurrence was similar for the 
TX group and the HX group, the HCCs of stages II 
and III recurred significantly (P = 0.003) more fre-
quently in the HX group than in the TX group 
(Table III). The incidence of tumor recurrence in 
stage IV-A was extremely high: 68% in the TX 
group and 60010 in the HX group. 
Sixty-seven (64%) of the 105 patients in the TX 
group and 48 (63%) of the 76 patients in the HX group 
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Fig. 4. Survival rates after liver TX and after HX for stages II to IV-A HCC in cirrhosis of the liver. 
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TABLE Ill. Tumor Recurrence and Causes of Death of HCC: TX 
vs. HX 
Recurrence Death with Death without 
of tumor tumor tumor 
(%) (%) (%) 
TX group 
Stage I (n = 4) 0(0) 0(0) I (25.0) 
Stage II (n = 19) 1 (5.3) 1 (5.3) 6 (31.6) 
Stage III (n = 23) 4 (17.4) 3 (13.0) 8 (24.8) 
Stage IV-A 40 (67.8) 38 (64.4) \0 (16.9) 
(n = 59) 
Total (n = \05) 45 (42.9) 42 (40) 25 (23.8) 
HX group 
Stage II (n = 19) 10 (52.6) 8 (42.1) 2 (10.5) 
Stage III (n = 25) 9 (36.0) 7 (28.0) 6 (24.0) 
Stage IV-A 19 (59.4) 17(53.1) 7 (21.9) 
(n = 32) 
Total (n = 76) 38 (50.0) 32 (42.1) 15(19.7) 
died during the follow-up period (Table III). Approxi-
mately two thirds of deaths were directly and in-
directly related to the tumor recurrence, both in the 
TX group and the HX group. Approximately one fifth 
of the patients in the TX group and in the HX group 
died of various causes that were not related to tumor 
recurrence. It is worth noting that tumor-related death 
among the patients with stage II and III HCC was 
statistically (P = 0.013) more frequent in the HX 
group than in the TX group (Table III). Tumor-re-
lated death was quite frequent among patients in stage 
IV-A tumor both in the TX group and the HX group 
(Table III). 
From the results presented above, the role of liver 
TX in the treatment of HCC has become somewhat 
clearer than it used to be. Liver TX and HX are 
equally effective treatments for HCC in terms of over-
all survival rates (Fig. I). In treating the HCCs devel-
oped in the cirrhotic liver, however, liver TX can pro-
vide higher survival rates in each stage of the pTNM 
classification than HX (Fig. 4). Tumor recurrence rate 
and deaths from recurrent HCC are significantly 
higher after HX than after liver TX for HCCs in stages 
II and III (Table III). 
CONCLUSION 
It is reasonable to conclude from our experience 
that liver TX has its definite role in the treatment of 
HCC, particularly when stage II and III HCCs are 
associated with cirrhosis of the liver. High recurrence 
rates of stage IV-A HCC both after transplant and 
resection are discouraging. The accelerated growth 
rate of HCC under immunosuppressive therapy has 
been documented [8]. Systematic neoadjuvant and ad-
juvant chemotherapy have been under investigation at 
our institute for the last 2 years. The preliminary re-
sults appear to be rather encouraging, but a longer 
follow-up is needed to determine the effectiveness of 
adjuvant chemotherapy. 
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